Key result
Attenuated autosomal dominant hypercholesterolemia phenotype in Tunisians warrants a specialized cascade screening protocol.
Why the study?
Early diagnosis and cascade screening are necessary to modify disease progression and outcomes in autosomal dominant hypercholesterolemia, especially given attenuated phenotypic expression in the Tunisian population.
Answers are grounded in this paper and cite their sources.
May support adapted FH screening in Tunisia; leaves open prospective validation before adoption.
Autosomal dominant hypercholesterolemia (ADH) is characterized by an isolated elevation of plasmatic lowdensity lipoprotein (LDL), which predisposes to premature coronary artery disease (CAD) and early death. ADH is largely due to mutations in the low-density lipoprotein receptor gene (LDLR), the apolipoprotein B-100 gene (APOB), or the proprotein convertase subtilisin/kexin type 9 (PCSK9). Early diagnosis and initiation of treatment can modify the disease progression and its outcomes. Therefore, cascade screening protocol with a combination of plasmatic lipid measurements and DNA testing is used to identify relatives of index cases with a clinical diagnosis of ADH. In Tunisia, an attenuated phenotypic expression of ADH was previously reported, indicating that the establishment of a special screening protocol is necessary for this population.
No takes yet. Share an insight, caveat, or question.
Jelassi et al. (2013) conducted a review in Autosomal dominant hypercholesterolemia. Cascade screening protocol was evaluated. An attenuated phenotypic expression of autosomal dominant hypercholesterolemia in the Tunisian population necessitates the establishment of a specialized cascade screening protocol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: